Intercept Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Intercept Pharmaceuticals

27/10/2023 19:34

* Intercept Pharmaceuticals Inc  ICPT.OQ   ICPT.O  is
expected
to show a rise in quarterly revenue when it reports  results 
    * The Morristown New Jersey-based  company is expected to
report 
a 14.1% increase in revenue to $88.51 million from $77.59
million a year ago, according to the mean estimate from 15
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Intercept
Pharmaceuticals
Inc is for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 12
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $19​, above​ its last closing price
of $18.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.48       -0.51      -0.14     Beat    72.5
 Mar. 31 2023  -0.64       -0.65      -0.77     Missed  -18.9
 Dec. 31 2022  0.25        -0.16      -0.50     Missed  -209.7
                                                        ​
 Sep. 30 2022  5.79        4.61       7.80      Beat    69.3
 ​​Jun.        -0.39       -0.49      -0.68     Missed  -39.5
 30 2022                                                
 Mar. 31 2022  -0.80       -0.90      -0.58     Beat    35.7​
 Dec. 31 2021  -0.98       -1.10      -1.23     Missed  -12.1
 Sep. 30 2021  -1.06       -1.09      -0.63     Beat    42.2
 This summary was machine generated October 27 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated